Brexit - What will the impact be?
With less than 100 days to go to Brexit what should the UK Pharmaceutical industry expect?
40 Total results for product and free and sample content found
By William Looney 30 Jul 2019
In today’s globalized market for medicines, national rules on pricing and access are abundantly shared and more transparent than opaque. In Vivo speaks to the UK branded industry’s negotiator for the latest five-year joint pricing pact with the government, Richard Torbett, who outlines, among other topics, five widely applicable precedents from the talks that can work in “getting to yes” – despite the fractious budgetary climate for health care evident in all major country markets.
By Tom Gallen 04 Jul 2019
Maximizing opportunities from digital technology, addressing environmental concerns and responding to the challenges of Brexit are among the Proprietary Association of Great Britain's top priorities as it enters its second century. The association invited guests from around the world to celebrate its centenary at a gala dinner in London on 17 June.
By Amanda Maxwell 03 Jul 2019
The recent no-deal Brexit notice from the UK government says that companies selling devices in the UK would need a "Responsible Person" in the UK if the firm is not based there. The government clarifies to Medtech Insight that such person must be physically present in the UK, and not simply have an address there.
By Maureen Kenny 03 Jul 2019
Clusters of excellence, competition as well as co-operation, Brexit, and aiming high. Danish Medicines Agency head Thomas Senderovitz talks national agencies and engagement in an interview with the Pink Sheet.
By Amanda Maxwell 02 Jul 2019
The UK government is introducing new registration requirements for medical devices in the event of a no-deal Brexit. They will be rolled out according to the risk class of products. But some fundamental questions have arisen.
By Jo Shorthouse 02 Jul 2019
As the EMA lowers the flags of the 28 EU nations that have flown outside its London offices for 24 years, and prepares to moves its HQ to the Netherlands, Scrip takes a look at Europe’s new pharma regulatory hub.
By Maureen Kenny 02 Jul 2019
The European Medicines Agency and drug regulators throughout the EU are having to invest huge amounts of time and effort in dealing with the fall-out from Brexit - and it hasn't even happened yet. Plans for working together on bigger issues agreed on a few years ago will likely have to change, senior regulator Thomas Senderovitz tells the Pink Sheet.
By Eleanor Malone 26 Jun 2019
Peter Martin, COO of Norgine, is concerned about the ‘mood music’ in the political environment in the UK, and warns about the risks of the UK leaving the EU without a deal in place.
No Records Found
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: